 |
(Photo = hugel) |
[Alpha Biz= Reporter Kim Sangjin] Hugel announced on the 30th that it has shipped the first batch of its botulinum toxin product Letybo (known as Botulax in Korea) to the U.S. Hugel received FDA approval for Letybo in 50-unit and 100-unit formulations earlier this year, and this export marks the beginning of its entry into the U.S. market.
To ensure a successful market entry, Hugel plans to leverage its partnership with U.S. distributor BENEV for distribution and marketing. Hugel will use BENEV's established sales network to distribute Letybo and will also conduct academic marketing and educational activities targeting medical professionals to communicate the safety and efficacy of the product.
Alphabiz Reporter Kim SangJin(letyou@alphabiz.co.kr)
